Anti-CD19 CAR-T Cells (eGFP)

Anti-CD19 CAR-T Cells (eGFP)
Artikelnummer
BPS78789
Verpackungseinheit
1 vial
Hersteller
BPS Bioscience

Verfügbarkeit: wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€

Applications: Use as positive control in anti-CD19 CAR-T cell development.Screen modulators of anti-CD19 CAR-T driven cytotoxicity.Design and optimize co-culture cytotoxicity assays for anti-CD19 specific CAR-T cell evaluation.

Background: CD19 (Cluster of Differentiation 19), also known as B-lymphocyte surface antigen B4, or CVID3, is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency disorders associated with impaired antibody production such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia). In addition, CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy.

Description: Anti-CD19 CAR-T Cells (eGFP) were produced by high-titer lentiviral transduction of human primary CD4+ and CD8+ T cells with SIN Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ eGFP) (#78775). These ready-to-use CAR (Chimeric Antigen Receptor)-T cells express an anti-CD19 CAR consisting of the ScFv (Single chain fragment variable) of anti-CD19 (clone FMC63) linked to a 2nd generation CAR containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1). The presence of eGFP (enhanced green fluorescent protein) allows for easy fluorescent detection of CAR-expressing cells.These CAR-T cells have been validated by flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.

Mycoplasma Testing: The cells have been screened to confirm the absence of Mycoplasma species.

Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.

Supplied As: Each vial contains ˃1 x 106 cells in 1 ml of CryoStor® CS10 (Stemcell Technologies #100-1061)

Uniprot: P15391

Warnings: Donors have been screened and determined negative for:Hepatitis B (anti-HBc EIA, HBsAg EIA)Hepatitis C (anti-HCV EIA)Human Immunodeficiency Virus (HIV-1/HIV-2 plus O)Human T-Lymphotropic Virus (HTLV-I/II)HIV-1/HCV/HBVWest Nile VirusTrypanasoma cruziNote: Testing cannot guarantee that any sample is completely virus-free. These cells should be treated as potentially infectious and appropriate Biological Safety Level 2 (BSL-2) precautions should be used.

Biosafety Level: Not applicable (BSL-1)

References: Depoil D., et al., 2008 Nat Immunol. 9: 63-72.
Van Zelm M.C., et al., 2006 N Engl J Med. 354: 1901-1912.
Goebeler M.E. and Bargou R., 2016 Leuk Lymphoma 57: 1021-1032.
Braendstrup P., et al., 2020 Cytotherapy 22: 57-69.
Mehr Informationen
Artikelnummer BPS78789
Hersteller BPS Bioscience
Hersteller Artikelnummer 78789
Verpackungseinheit 1 vial
Mengeneinheit STK
Produktinformation (PDF) Download
MSDS (PDF)
×